Haematological safety of perinatal zidovudine in pregnant HIV-1-infected women in Thailand: secondary analysis of a randomized trial.

ABSTRACT:

Objectives

To respond to the primary safety objective of the Perinatal HIV Prevention Trial 1 (PHPT-1) by studying the evolution of haematological parameters according to zidovudine exposure duration in HIV-1-infected pregnant women.

Design

Multicenter, randomized, double-blind, controlled trial of different durations of zidovudine prophylaxis.

Setting

27 hospitals in Thailand.

Participants

1,436 HIV-infected pregnant women in PHPT-1.

Intervention

Zidovudine prophylaxis initiation at 28 or 35 wk gestation.

Outcome measures

Haemoglobin level, leucocytes, total lymphocyte counts, and absolute neutrophil counts were measured at 26, 32, and 35 wk and at delivery. The evolution of haematological parameters was estimated between 26 and 35 wk (zidovudine

SUBMITTER: Briand N 

PROVIDER: S-EPMC1863515 | biostudies-literature | 2007 Apr

REPOSITORIES: biostudies-literature